Thus, therapy in Bcl-2-mediated resistance to radiotherapy or chemotherapy, via targeting KHDC1L to inhibit Bcl-2, may be a novel strategy in HNSCC. Here, BCL2 is linked to head and neck squamous cell carcinoma.